Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | BRD2 | P25440 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31735610 | 1.00 | BRD4 (1.00) | BRD4MEN1KMT2ARAB9ALMNA | |
| SCHEMBL18124120 | 0.88 | BRD4 (1.00) | BRD4MEN1KMT2ARAB9ALMNA | |
| SCHEMBL31735700 | 0.88 | BRD4 (1.00) | BRD4MEN1KMT2ARAB9ALMNA | |
| SCHEMBL17581483 | 0.78 | BRD4 (0.63) | BRD4CREBBPJAK2BRD2 | |
| SCHEMBL29422776 | 0.77 | BRD4 (0.64) | BRD4CREBBP | |
| SCHEMBL859173 | 0.77 | BRD4 (0.64) | BRD4CREBBP | |
| SCHEMBL31735707 | 0.76 | BRD4 (0.65) | BRD4CREBBPJAK2BRD2BRD3 | |
| SCHEMBL19998616 | 0.76 | BRD4 (0.65) | BRD4CREBBPJAK2BRD2BRD3 | |
| SCHEMBL24717312 | 0.75 | BRD4 (0.60) | BRD4CREBBPJAK2BRD2BRD3 | |
| SCHEMBL24913618 | 0.75 | BRD4 (0.79) | BRD4LMNACREBBPJAK2BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-2970265-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2970265-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2018-03-15 | — | — | US | disclosed |
| US-9822109-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822109-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822109-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2016-03-10 | — | — | US | disclosed |
| EP-2970265-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014145051-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ZHANG JIAZHONG (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885MEN1 672/4885KMT2A 4032/4885 |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885MEN1 672/4885KMT2A 4032/4885 |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885MEN1 672/4885KMT2A 4032/4885 |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885MEN1 672/4885KMT2A 4032/4885 |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885MEN1 672/4885KMT2A 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.